Benign melanocytic tumors

Chapter 41 Benign melanocytic tumors









5. Explain the natural developmental history of melanocytic nevi.
Melanocytic nevus cells are derived from melanocytes and differ from normal epidermal melanocytes in a number of ways. They are no longer dendritic; they do not distribute melanin to surrounding keratinocytes; and they are less metabolically active. Melanocytic nevi are benign clonal proliferations of cells expressing the melanocytic phenotype, and are thought to be derived from precursor cells that acquire genetic mutations. These mutations are thought to activate proliferative pathways and/or or suppress apoptosis, allowing for the accumulation of melanocytic cells in the skin. The type of nevus that is formed is thought to be dependent upon the specific mutation, as well as local environmental factors. B-Raf mutations are commonly seen in acquired melanocytic nevi. Acquired melanocytic nevi are thought to begin as a proliferation of nevus cells along the dermal–epidermal junction (forming a junctional nevus; Fig. 41-1A). With continued proliferation of nevus cells, they extend from the dermal–epidermal junction into the dermis (forming a compound nevus). The junctional component of the melanocytic nevus may resolve, leaving only an intradermal component (intradermal nevus; Fig. 41-1B). However, it should be stressed that there is debate regarding the direction of nevus growth.

Melanocytic nevi form naturally, possibly due to ultraviolet light exposure, from the ages of 6 months to 40 years and later. They may also resolve spontaneously. However, the appearance or disappearance of any melanocytic lesion should be brought to the attention of a physician.


Cane JF, Trainor PA: Neural crest stem and progenitor cells, Annu Rev Cell Dev Biol 22:267–286, 2006.


Grichnik J: Melanoma, nevogenesis, and stem cell biology, J Invest Dermatol 128:2365–2380, 2008.


6. What is a halo nevus?
A halo nevus, also known as a Sutton’s nevus or leukoderma acquisitum centrifugum, is a melanocytic nevus with a surrounding well-circumscribed annulus of hypo- or depigmented skin (Fig. 41-1C). Halo nevi can be solitary or multiple and generally affect individuals under the age of 20 years. In general, those patients with halo nevi have an overall increased number of melanocytic nevi. Halo nevi are commonly associated with vitiligo, with ∼20% to 50% of vitiligo patients demonstrating halo nevi. Conversely, ∼15% to 25% of patients with halo nevi have vitiligo. Although both halo nevi and vitiligo may look similar clinically, recent studies strongly suggest that halo nevi and vitiligo have separate pathogenetic mechanisms. Although not completely understood, the pathogenesis of halo nevi is thought to be related to 1) an immune response against antigenically altered nevus cells or 2) a cell-mediated or humoral immune response against nonspecifically altered nevus cells. It is not completely understood whether this represents an abnormal immunologic response or whether the immune system is recognizing an atypical clone of nevomelanocytes.

Although most pigmented lesions with halos are benign, malignant melanoma can rarely be seen with an associated halo. If a pigmented lesion has an irregular border and halo or shows other atypical features, it should be biopsied.


De Vijlder HC, Westerhof W, Schreuder GM, et al: Difference in pathogenesis between vitiligo vulgaris and halo nevi associated with vitiligo is supported by an HLA study, Pigment Cell Res 17:270–274, 2004.




Apr 26, 2016 | Posted by in Dermatology | Comments Off on Benign melanocytic tumors

Full access? Get Clinical Tree

Get Clinical Tree app for offline access